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Background: Endothelial dysfunction is associated with vascular risk factors such as dyslipidemia, hypertension, and
diabetes, leading to coronary atherosclerosis. Sympathetic stress using cold-pressor testing (CPT) has been used to
measure coronary endothelial function in humans with positron emission tomography (PET) myocardial blood flow
(MBF) imaging, but is not practical in small animal models. This study characterized coronary vasomotor function in mice
with [11C]acetate micro-PET measurements of nitric-oxide-mediated endothelial flow reserve (EFRNOM) (adrenergic-stress/
rest MBF) and myocardial oxygen consumption (MVO2) using salbutamol β2-adrenergic-activation.
Methods: [11C]acetate PET MBF was performed at rest + salbutamol (SB 0.2, 1.0 μg/kg/min) and norepinephrine
(NE 3.2 μg/kg/min) stress to measure an index of MBF response. β-adrenergic specificity of NE was evaluated by
pretreatment with α-adrenergic-antagonist phentolamine (PHE), and β2-selectivity was assessed using SB.
Results: Adjusting for changes in heart rate × systolic blood pressure product (RPP), the same stress/rest MBF ratio
of 1.4 was measured using low-dose SB and NE in normal mice (equivalent to human CPT response). The MBF
response was correlated with changes in MVO2 (p = 0.02). Nitric oxide synthase (NOS)-inhibited mice (N
g-nitro-L-
arginine methyl ester (L-NAME) pretreatment and endothelial nitric oxide synthase (eNOS) knockout) were used to
assess the EFRNOM, in which the low-dose SB- and NE-stress MBF responses were completely blocked (p = 0.02).
With high-dose SB-stress, the MBF ratio was reduced by 0.4 following NOS inhibition (p = 0.03).
Conclusions: Low-dose salbutamol β2-adrenergic-stress [11C]acetate micro-PET imaging can be used to measure
coronary-specific EFRNOM in mice and may be suitable for assessment of endothelial dysfunction in small animal
models of disease and evaluation of new therapies.
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Coronary artery disease (CAD) is a leading cause of
death worldwide, and endothelial dysfunction (ED) is an
early marker in the progression of coronary atheroscler-
osis. The principal function of the coronary endothelium
is auto-regulation of microvascular perfusion in response* Correspondence: RAdeKemp@ottawaheart.ca
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in any medium, provided the original work is pto the changing metabolic demands of the heart [1]. Assess-
ment of coronary endothelial function is important as ED
can accelerate the progression of several cardiac-related dis-
eases, including hypertension, diabetes, and atherosclerosis
[2]. With advanced CAD, endothelial vasodilatation can be
severely inhibited, or paradoxically, vasoconstriction can
occur in response to metabolic or sympathetic stress [3].
Limited in vivo methods are available to investigate ED: 1)
invasive catheterization of epicardial coronary arteries
with Doppler ultrasound flow response to intracoronaryan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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2) non-invasive echocardiography measurement of large
peripheral arteries with flow-mediated dilation (FMD)
response to shear stress [5], and 3) non-invasive myo-
cardial blood flow (MBF) positron emission tomography
(PET) sympathetic-stress response to cold-pressor test-
ing (CPT) [6,7]. Immersion of the hand or foot in ice
water for CPT predominantly releases the catecholamine
norepinephrine and increases systemic blood pressure and
heart rate. The correspondingly higher heart rate × sys-
tolic blood pressure product (RPP) is an index of cardiac
work correlated to an increase of myocardial oxygen con-
sumption [8].
In angiographically normal human coronary arteries,
the non-invasive PET CPT flow increase is highly corre-
lated with the intracoronary Doppler flow response to
ACh infusion [9], whereas patients with abnormal CPT
MBF response (<40%) have increased risk of clinical
cardiovascular events [10]. The CPT response is predom-
inantly adrenergic-receptor mediated and endothelium-
dependent [11,12], representing only a fraction of the
maximal vasodilatation usually assessed with pharmaco-
logic stressors that directly target adenosine receptors/
reuptake at the coronary vascular smooth muscle [13].
The PET perfusion tracers [13 N]ammonia and [15O]
water have been used to quantify MBF in rats [14,15];
however, their long positron ranges (RMS approximately
0.6 and 1.0 mm, respectively) with adjacent liver and
lung uptake are not ideal characteristics for PET imaging
of the approximately 1-mm thickness myocardium in
mice [16]. [11C]acetate has a shorter positron range
(0.4 mm), minimal liver and lung uptake in mice, and a
washout rate (k2) which is accepted as an index of oxida-
tive metabolism in human and animal studies [15]. Add-
itionally, the tracer uptake rate (K1) has been proposed
as an index of MBF and used to derive absolute flow
values in humans [17] and rats [15], making it an at-
tractive candidate for PET imaging of MBF in mice.
The goal of this study was to assess the coronary-
specific endothelium-dependent MBF response using
micro-PET imaging with low-dose SB, as an alternative
to sympathetic stress using norepinephrine (NE) or CPT
PET imaging that is well-established in humans [6,7]. SB
is a selective β2-adrenergic agonist and potent broncho-
dilator, commonly administered in aerosol form to treat
the symptoms of asthma. However, it is also known that
the β2-adrenergic receptors in the heart are expressed
mainly in the small arteries and precapillary arterioles
and therefore may be an ideal target to selectively probe
the vasodilator function of the coronary microvascula-
ture [18]. If successful, SB-stress PET imaging has the
potential for direct translation to human studies investi-
gating the progression of endothelial dysfunction and
the evaluation of new therapies.Methods
Animal preparation
Normal adult male C57BL/6 J mice (6 to 10 weeks old;
Charles River, Montreal, Canada) weighing 27 ± 4 g (n = 40)
and adult male endothelial nitric oxide synthase knockout
(eNOS−/−) 129S6.129P2(B6)-Nos3tm1Unc/J mice (6 to
8 weeks old; Jackson Laboratory, Bar Harbor, ME, USA)
weighing 26 ± 6 g (n = 5) were included in this study.
Physiologic monitoring
Mice were anesthetized with 1% to 2% isoflurane (Abbott
Laboratories, Montreal, Canada) and monitored using ex-
ternal probes (SA Instruments Inc., Stony Brook, NY,
USA). Venous catheters were inserted into one or both
lateral tail veins for adrenergic stressor and PET radio-
tracer administration. Blood pressure was monitored with
a pressure analyzer connected to an ultra-miniature fiber
optic sensor (SA Instruments Inc., Stony Brook, NY, USA)
attached to a PE10 polyethylene catheter (Becton Dickinson,
Franklin Lakes, NJ, USA) inserted into the carotid artery.
For validation of the PET radiotracer measurements in ar-
terial blood (tracer kinetic input function), the same PE10
carotid catheter method was used for manual blood with-
drawal (n = 5).
Three experimental groups were used (Table 1) with
n = 5 each as follows: 1) normal control mice under SB-
stress and NE-stress ± pretreatment with phentolamine
(PHE), an α-adrenergic receptor antagonist; 2) NOS-
inhibition mice pretreated using Ng-nitro-L-arginine me-
thyl ester (L-NAME) under SB-stress and NE-stress; and
3) transgenic knockout eNOS−/− mice under NE-stress.
The catecholamine NE was used at 1.6, 3.2, and 5.6 μg/kg/
min (Hospira, Lake Forest, IL, USA) [19], phentolamine
(Novartis, Quebec, Canada) at 1.5 mg/kg I.V. administered
5 min before NE-stress PET imaging [20], and SB was
used at high and low doses of 1.0 and 0.2 μg/kg/min [21].
The middle dose of 3.2 μg/kg/min NE was selected as
the reference standard (NE control). Pretreatment with
L-NAME (Sigma-Aldrich, Oakville, Canada), a non-selective
systemic nitric oxide synthase inhibitor, was adminis-
tered at 40 to 60 mg/kg/day via drinking water for
1 week [22]. All animal experiments were performed in
accordance with the Canadian Council on Animal Care
guidelines and ethics approval by the University of
Ottawa Animal Care Committee.
PET imaging
Rest and adrenergic stress (NE and SB) myocardial
blood flow index (MBFi) values were measured with
[11C]acetate micro-PET to assess the coronary vasodila-
tation flow reserve as stress/rest MBFi ratio. Validation
of [11C]acetate properties as a myocardial perfusion
tracer has been confirmed recently [15,23]. For the stress
study, a constant infusion of NE or SB was initiated for
Table 1 Experimental groups used for adrenergic stress characterization of coronary endothelial function
Adrenergic
stress agent








NE Alpha-agonist + beta-agonist 3.2 Alpha peripheral vasoconstriction beta1
cardiac inotropy and chronotropy beta2
coronary and bronchial dilatation
5 5 5
PHE + NE Alpha-antagonist + beta-agonist 3.2 Alpha peripheral vasodilatation beta1
cardiac inotropy and chronotropy beta2
coronary and bronchial dilatation
5
SB high-dose Beta2-agonist 1.0 Beta2 coronary and bronchial dilatation 5 5
SB low-dose Beta2-agonist 0.2 Beta2 coronary and bronchial dilatation 5 5
eNOS, Endothelial nitric oxide synthase; NE, norepinephrine; PHE, phentolamine; SB, salbutamol.
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infusion of NE or SB for 10 min. Five minutes later, a
slow-bolus injection of 25 ± 9 MBq of [11C]acetate in 75-
μL saline solution was administered using a syringe
pump at a rate of 100 μL/min into the tail vein. PET im-
aging was performed with a 10.0-cm trans-axial, 12.7-cm
axial field-of-view scanner (Inveon DPET, Siemens,
Knoxville, TN, USA) with an isotropic spatial resolution of
1.4 mm. List-mode PET data were acquired for 5 min and
binned into 18 dynamic frames of 12 × 10 s and 6 × 30
s. Dynamic images were reconstructed with 0.34 × 0.34 ×
0.80 mm pixel size using 12 iterations of OSEM3D includ-
ing corrections for detector dead-time, isotope decay, geo-
metric efficiency, random coincidences, and system
sensitivity, but not attenuation or scatter [24].
Tracer kinetic modeling
From the reconstructed images, kinetic analysis of the
myocardial time-activity data was performed semi-
automatically using FlowQuant© v2.4 software (Univer-
sity of Ottawa Heart Institute, Ottawa, Ontario, Canada)
as previously described [25,26].
[11C]acetate blood time-activity curves (TACs) were
obtained from an image-derived region-of-interest on
the inferior vena cava (VC) using Inveon™ Research
Workplace (IRW) software (Siemens; Knoxville, TN,
USA). A 50% intensity contour-region-of-interest (ROI)
was defined semi-automatically, on a 10-s frame with
the highest VC activity (typically 30 to 40 s after injec-
tion), using a trans-axial slice 2 to 5 mm below the kid-
neys, avoiding activity spillover from surrounding organs
during the dynamic scan (Figure 1A). The maximum ac-
tivity in the VC region was measured at all time points,
and the resulting blood TAC was shifted in time (+10 s)
to match the initial upslope and peak activity of the ar-
terial blood samples described below. This inferior VC
image-derived input function (IDIF) was then used as in-
put to a one-tissue-compartment model of [11C]acetate
kinetics in the FlowQuant© program. The tracer kinetic
model was fit to the left ventricular (LV) myocardium
TAC data in each polar-map sector to estimate thetracer uptake rate (K1) as a MBFi [mL/min/g] and the
tracer washout rate (k2) as an index of myocardial oxy-
gen consumption (MVO2) [min
−1] (Figure 1C) [17].
The stress/rest ratio of k2 values represents an index of
the MVO2 stress response. The ratio of stress/rest K1 is an
index of the MBF response (Figure 1C). A myocardial oxy-
gen extraction fraction index (OEFi) was also estimated as
the ratio of MVO2/MBFi. The LV-average polar-map
values of stress/rest MBFi were also adjusted for changes
in the RPP, reflecting alterations in cardiac demand and
associated metabolic-dependent changes in flow [27]. The
RPP-adjusted values were calculated as follows: [stress/rest
MBFi]/[stress/rest RPP] = [stress MBFi/RPP]/[rest MBFi/
RPP] and reported as sympathetic-stress myocardial flow
reserve (sMFR). The specific changes in sMFR with NOS
inhibition are reported as the nitric-oxide-mediated endo-
thelial flow reserve (EFRNOM).
Arterial blood sampling
Accuracy of the inferior VC IDIF described above was
confirmed experimentally by simultaneous blood sampling
from the carotid artery (standard (STD)) during [11C]acet-
ate imaging at rest (n = 5) according to the following time
sequence: 0, 10, 20, 30, 40, 45, 50, 55, 60, 70, 80, and 90 s
and 2, 3, and 5 min, using a total blood volume of 0.5 ±
0.1 mL. The arterial blood samples were diluted in saline
to a standard volume of 300 μL. The activity concentration
(Bq/mL) was then measured using a calibrated well-
counter (Packard Cobra II, Canberra, Meriden, CT, USA)
and decay-corrected to the PET scan start time. The STD
arterial TAC was used as input to the same tracer kinetic
model described above for comparison of the MBFi values
to those obtained using the inferior VC IDIF.
Statistical analysis
Areas under the arterial blood curve and the derived MBFi
values were compared between the VC and STD curves
using a two-tailed paired t-test. Hemodynamic and MBF
parameters were compared during SB-stress and PHE +
NE-stress vs. NE control using F-tests and two-tailed un-
paired t-tests. To assess physiologic changes in oxygen
Figure 1 Reorientation and sampling of myocardial ROI, metabolite-corrected blood input functions and myocardial TACs, and MBFi K1
polar-maps. (A) Reorientation and sampling of the myocardial region of interest (ROI) in the transverse, vertical long-axis, and horizontal long-axis
planes (FlowQuant© software). The image-derived input function (IDIF) from the inferior vena cava (VC) blood region (red) was created semi-automatically.
(B) Metabolite-corrected blood input functions and myocardial TACs at rest and stress. (C) Myocardial blood flow index (MBFi) K1 polar-maps derived using
the inferior VC blood input at Rest, low-dose salbutamol Stress, and stress/rest (Flow Reserve).
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ratio), and MVO2 were compared between groups (PHE +
NE-stress, SB-stress) using one-way ANOVA and two-
tailed unpaired t-tests. Hemodynamic and MBFi parame-
ters at rest were compared in the NOS-inhibition and
eNOS-knockout groups vs. NE control using a one-way
ANOVA. Adrenergic-stress MBFi was compared between
control and NOS-inhibition groups using F-tests and posthoc two-tailed unpaired t-tests. All data were expressed as
mean ± standard deviation (SD). A p value less than 0.05
was considered statistically significant.
Results
Arterial blood input function validation
The carotid artery STD and the inferior VC blood input
curves are shown in Figure 2. The time-shifted (10-s
Figure 2 Average blood input functions following [11C]acetate injection and MBFi polar-maps using carotid artery STD and inferior VC
blood inputs. (A) Average blood input functions following [11C]acetate injection in normal control mice (n = 5). Curves are normalized relative to
the maximum activity of the carotid artery reference standard (STD) samples. (B) Myocardial blood flow index (MBFi) polar-maps derived using
the carotid artery STD and inferior vena cava (VC) blood input curves. There were no significant differences in blood input areas-under-the-curve
(AUCs) or MBFi values.
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the blood curve sampled from the carotid artery, demon-
strating similar shapes and no significant difference in the
area-under-the-curve (p = 0.35). The corresponding MBFi
values were not significantly different (3.1 vs. 2.9 mL/min/g,
p = 0.68). Regional variation in the difference between
the two MBFi polar-maps was also low (13% coefficient-
of-variation across polar-map sectors), suggesting that
no regional bias was induced by using the time-shifted
inferior VC blood input.
Selective beta-adrenergic MBF response
The effects of β-specific and β2-selective adrenergic stimu-
lation on MBF are shown in Figure 3. In contrast to the
NE-stress response (with or without PHE), the proposed
β2-selective agonist SB had no significant effect on the
hemodynamic parameters (Table 2). A dose-dependent in-
crease of 39% to 75% in stress vs. rest MBFi was observed
(p < 0.0001), suggesting a cardiac-specific effect of SB at
both doses (Table 3). There was no significant effect of
body weight on the measured MBFi values between
groups (ANOVA p = 0.08).
The RPP-adjusted sMFR in the PHE +NE group (1.81)
was increased by 12% compared to the unadjusted MBFi
ratio, resulting in values very close to the high-dose SB
results (1.78). Conversely, sMFR in the NE control group
(1.39) was decreased by 17% compared to the unadjusted
MBFi ratio, resulting in values equivalent to the low-
dose SB group (1.39). Therefore, it appears that only SB,Figure 3 Hemodynamics and myocardial blood flow index (MBFi) respo
norepinephrine 3.2 μg/kg/min, PHE phentolamine pretreatment, SB salbutam
(green), SB-stress (blue). *p < 0.05 vs. NE Control.through selective activation of the β2-adrenergic receptors,
was able to produce a myocardial flow response without
significantly changing the systemic hemodynamic parame-
ters, as opposed to NE with or without PHE pretreatment.
NO-mediated myocardial blood flow response
The specific NO-mediated (i.e. endothelial-dependent)
component of the adrenergic-stress MBFi responses is
shown in Figure 4 and Table 3. Despite small hyperten-
sive changes, the resting MBFi values in the eNOS-
knockout group (3.3 ± 0.6) were similar to the normal
controls (3.4 ± 1.3, p = 0.80) and NOS-inhibition groups
(4.0 ± 1.3, p = 0.24).
With NE-stress, the NOS-inhibition and eNOS-
knockout groups had similar endothelial-dependent re-
ductions in MBFi ratio compared to the NE control
(39% and 33%, respectively), with values close to unity
(0.96 and 0.99) confirming that the RPP-adjusted NE-
stress response was NO-mediated, and therefore pre-
dominantly reflected the coronary-specific EFRNOM
(Figure 5).
The high-dose and low-dose SB groups under NOS in-
hibition showed similar decreases in MBFi ratio (−0.37
and −0.4, respectively) and MVO2 ratio (−0.2 and −0.15,
respectively) compared to normal mice at the same dose.
However, only the low-dose SB group had a MBFi ratio
close to unity (0.99), with or without RPP adjustment.
Similar to NE-stress in the NOS-inhibition and eNOS-
knockout groups above, the low-dose SB flow responsense to adrenergic stress agents in healthy normal mice. NE
ol High 1.0 μg/kg/min, SB salbutamol Low 0.2 μg/kg/min. NE-stress
















Normal NE 3.2 25 ± 3 409 ± 29 74 ± 12 30,018 ± 4,699 402 ± 25 89 ± 11 35,639 ± 4,557
SB 0.2 27 ± 1 423 ± 21 88 ± 12 37,430 ± 5,850 433 ± 20 87 ± 14 37,593 ± 6,140
SB 1.0 26 ± 1 432 ± 13 87 ± 13 37,729 ± 6,275 434 ± 11 85 ± 14 36,884 ± 6,587
PHE + NE 3.2 25 ± 3 435 ± 32 95 ± 17 40,967 ± 6,151 476 ± 36* 77 ± 17 36,390 ± 7,695
eNOS knockout NE 3.2 27 ± 6 355 ± 41*,** 107 ± 19*,** 38,516 ± 11,584 373 ± 42*,** 114 ± 17*,** 43,018 ± 11,214
NOS inhibition NE 3.2 28 ± 3 454 ± 22* 79 ± 20 36,024 ± 10,195 453 ± 24* 85 ± 22 38,511 ± 10,921
SB 0.2 31 ± 3 404 ± 44 90 ± 10 36,877 ± 5,278 409 ± 43 89 ± 8 37,021 ± 5,305
SB 1.0 30 ± 2 408 ± 32 91 ± 11 37,247 ± 5,613 406 ± 30 91 ± 12 37,072 ± 6,122
bpm, heart beats per minute; SBP, systolic blood pressure; RPP, heart rate × systolic blood pressure product; eNOS, endothelial nitric oxide synthase; NE,
norepinephrine; SB, salbutamol. NOS inhibition = L-NAME pretreated. Values are mean ± standard deviation. *p < 0.05 vs. normal NE. **p < 0.05 vs.
NOS-inhibition NE.
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(Figure 5). In contrast, the high-dose SB group main-
tained a MBF response significantly greater than unity
(1.39), suggesting that the β2-adrenergic agonist is only
partially endothelial-dependent and NO-mediated at this
dose, with the remaining increase being dependent on
non-NO-mediated mechanisms. With SB-stress, NOS-
inhibition mice showed no significant hemodynamic
changes vs. normal controls (Table 3). These results
demonstrate that the high-dose and low-dose SB-stress/
rest flow responses were partially and completely NO-
mediated, respectively. Low-dose SB appeared to specif-
ically reflect the NO-mediated endothelium-dependent
vasodilatation (i.e., EFRNOM).Discussion
To our knowledge, this is the first study to demonstrate the
use of SB-stress to selectively measure the NO-mediated







Normal NE 3.2 1.68 ± 0.42 1.58 ± 0.2
SB 0.2 1.39 ± 0.27 1.37 ± 0.1
SB 1.0 1.75 ± 0.25*** 1.73 ± 0.2
PHE + NE 3.2 1.61 ± 0.51 1.95 ± 0.4
eNOS knockout NE 3.2 1.12 ± 0.23* 1.57 ± 0.3
NOS inhibition NE 3.2 1.03 ± 0.23* 1.35 ± 0.2
SB 0.2 0.99 ± 0.15*,** 1.17 ± 0.0
SB 1.0 1.38 ± 0.17**,*** 1.58 ± 0.3
MBFi, myocardial blood flow index; MVO2, myocardial oxygen consumption; OEFi =
pressure product; eNOS, endothelial nitric oxide synthase; NE, norepinephrine; SB, s
MBFi ratio/RPP ratio; NOS inhibition = L-NAME pretreated. Nitric-oxide-mediated end
standard deviation (coefficient of variation × 100%). *p < 0.05 vs. normal NE. **p < 0PET imaging. Our findings shed new light on the mecha-
nisms and effects of coronary β-specific vasodilatation
in vivo. Previous results have only been obtainable using in-
vasive or ex vivo methodologies, which are not feasible or
optimal for application in mouse models of endothelial dys-
function. Low-dose SB-stress PET imaging appears to be
well suited to measure coronary-specific NO-mediated
endothelial vasoreactivity, e.g., for preclinical investigation
of targeted therapies to improve NO bioavailability and
contractile function of the vascular endothelium [20].Beta-adrenergic myocardial blood flow response
In the present study, the catecholamine NE, a potent α1, α2,
moderate β1, and potent β2 agonist, was selected initially
for its well-established role in the human CPT response
[28]. Similar to dobutamine, the positive chronotropic and
inotropic effects of NE on heart rate and blood pressure
were observed [29]. Control of coronary blood flow during








8 0.99 ± 0.29 1.19 ± 0.10 1.39 ± 0.35 (25%)
5 1.00 ± 0.10 1.00 ± 0.02* 1.39 ± 0.27 (19%)
3*** 1.00 ± 0.14 0.98 ± 0.02* 1.78 ± 0.25*** (14%)
5 1.27 ± 0.35 0.89 ± 0.15* 1.81 ± 0.57 (32%)
4 1.46 ± 0.50 1.13 ± 0.04 0.99 ± 0.20* (20%)
0 1.35 ± 0.29 1.07 ± 0.02* 0.96 ± 0.22* (23%)
8*,** 1.20 ± 0.12** 1.00 ± 0.03* 0.98 ± 0.15*,** (15%)
7*** 1.16 ± 0.29 0.99 ± 0.02* 1.39 ± 0.17**,*** (12%)
MVO2/MBFi, oxygen extraction fraction index; RPP, heart rate × systolic blood
albutamol. Sympathetic-stress myocardial flow reserve (sMFR) RPP-adjusted =
othelial flow reserve (EFRNOM) values shown in italics. Values are mean ±
.05 vs. normal SB with same dose. ***p < 0.05 vs. low-dose SB (0.2 μg/kg/min).
Figure 4 Hemodynamics and myocardial blood flow index (MBFi) response to adrenergic stress agents norepinephrine (NE) and salbutamol
(SB) with and without NOS inhibition. Normal controls are compared to NOS inhibition (L-NAME pretreatment), and endothelial nitric oxide
synthase knockout mice (eNOS knockout). NE-stress (green), SB-stress (high dose, dark blue; low dose, light blue). *p < 0.05 vs. NE Control.
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good correlation (r2 = 0.65) was observed between the
MFR and MVO2 indices across all groups (Figure 6),
equivalent to that observed in previous human studies
[31]. The selected NE control dose was targeted for meas-
urement of the maximal sMFR response associated with
endothelial-dependent activation without increasing the
heart rate. Adjustment of the MBF response for changes
in the stress/rest RPP ratio was performed to account for
any change in oxygen demand induced with NE-stress, to
obtain a specific measure of the EFRNOM [32]. The known
relationship between oxygen demand and the metabolic-
dependent signaling pathways for vasodilatation wouldFigure 5 Flow reserve response to β-adrenergic vasodilator stressors,
min, SB High salbutamol 1.0 μg/kg/min, SB Low salbutamol 0.2 μg/kg/min.
(EFRNOM) and non-NO-mediated microvascular flow responses. NE-stress (gr
NOS inhibition.otherwise be confounding factors, precluding specific
measurement of the endothelial-dependent vasodilatation.
After RPP adjustment, the NE control values of sMFR in
the normal mice were equal to the low-dose SB values (1.4-
fold increase), reflecting a similar level of endothelium-
dependent (and NO-mediated) stimulation. In the high-dose
SB and PHE+NE groups, the RPP-adjusted MBFi response
(1.8-fold increase) was higher compared to the NE control
and low-dose SB, suggesting added effects from other mech-
anisms of vasodilatation. With NE- and SB-stress (high- or
low-dose) in the normal control mice, there was a matched
increase in MBFi and MVO2, i.e., OEFi ratio values
were very close to 1.0 confirming the close coupling ofNOS inhibition, and eNOS knockout. NE norepinephrine 3.2 μg/kg/
High-dose SB flow reserve is the sum of NO-mediated endothelial
een), SB-stress (blue). *p < 0.05 NOS inhibition vs. same stressor without
Figure 6 NOS-inhibition effects on myocardial blood flow index response (MBFi ratio) to adrenergic stress agents. Norepinephrine (NE)
1.6, 3.2, and 5.6 μg/kg/min and salbutamol (SB) low-dose 0.2 μg/kg/min and high-dose 1.0 μg/kg/min. (A) MBFi vs. RPP response (stress/rest), (B)
MBFi adjusted to the mean RPP-ratio (MBFiadj ratio), (C) MBFi vs. oxygen metabolism response (stress/rest MVO2 ratio), and (D) adjusted MBFi vs
MVO2 ratio. After adjusting for the RPP-effects on MBFi, NOS inhibition results in proportional reductions in the MBFi and MVO2 responses to
adrenergic stress (arrows shown in (D)).
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stress, the observed increase in MVO2 without any change
in the RPP is somewhat unexpected but may be related to
secondary metabolic effects resulting from activation of β2-
receptors on the cardiac myocytes.
NO-mediated myocardial blood flow response
Administration of L-NAME, a NOS inhibitor, leads to a
decrease in NO bioavailability and creates an imbalance
between vasodilatation and vasoconstriction, resulting in
a trend towards increased peripheral blood pressure
(Table 2) from unopposed α-adrenergic tone [22].
At rest, MBFi was not significantly changed in the
NOS-inhibition or eNOS-knockout groups, consistent
with previous literature [33]. The NOS-inhibition and
eNOS-knockout groups showed a complete inhibition of
the sMFR response to NE-stress. With intravenous SB,
our non-invasive EFRNOM results using [
11C]acetate
micro-PET were similar to previous invasive intracoron-
ary infusion studies showing that a hyperemic response
was partially or totally blocked in the presence of a NOS
inhibitor [3,12].
With high-dose and low-dose SB-stress, the same de-
crease in sMFR under NOS inhibition was observed
compared to normal control mice without NOS inhib-
ition, suggesting a similar magnitude of NO-mediated
vasodilatation (EFRNOM approximately 1.4-fold increase).
Low-dose SB resulted in an exclusively NO-mediatedendothelium-dependent effect, where MBFi under NOS
inhibition was 100% inhibited with or without RPP ad-
justment (therefore reflecting EFRNOM). This is in con-
trast to high-dose SB, where only a 50% reduction of the
total sMFR was observed with NOS inhibition. This obser-
vation may be explained by the presence of β2-adrenergic
receptors on the coronary vascular endothelium and
smooth muscle cells [34]. High-dose SB may activate both
components of the coronary vessel wall, as well as other
non-NO-mediated signaling mechanisms, whereas low-dose
SB seems to produce a coronary-specific and endothelium-
dependent NO-mediated activation [12].
Compared to the complete NOS inhibition of the MBF
response with low-dose salbutamol, there was only a partial
reduction in the MVO2 response compared to controls,
corresponding to a significantly increased OEFi ratio (1.2
vs. 1.0; p < 0.05). A similar trend was observed in the other
NOS-inhibition and eNOS-knockout groups, but the
changes in OEFi ratio did not reach statistical significance,
possibly due to the small sample size. These changes in the
OEFi ratio suggest an uncoupling of metabolism and blood
flow, as might be expected in these animal models of endo-
thelial dysfunction. Further studies are needed to fully in-
vestigate the physiologic mechanism(s) of these observed
changes in oxidative metabolism.
These results demonstrate a strong potential for the
proposed low-dose SB-stress method to be translated to
humans as a coronary adrenergic stress test of NO-
Croteau et al. EJNMMI Research  (2014) 4:68 Page 10 of 11mediated endothelial function (Figure 5). For future transla-
tion to clinical PET imaging studies, the clinical safety pro-
file of intravenous SB is well-established in the treatment
of acute asthma, using doses that are the same as those
proposed in the present study to measure the endothelial-
dependent flow reserve (low-dose SB = 0.2 μg/kg/min ×
10 min) [35].
Kinetic modeling analysis
As a well known metabolic radiotracer for oxygen con-
sumption, [11C]acetate has also been validated as a ra-
diotracer for MBF imaging in humans and rats. There is
good correlation between MBF values obtained with
compartment modeling of [11C]acetate and [15O]water
or [13 N]ammonia [23]. In the single-tissue compartment
model, the myocardial efflux of [11C]CO2 and the clear-
ance of other labeled metabolites are typically combined
in a single rate constant (k2) reflecting the rate of oxida-
tive metabolism. An average blood metabolite correction
has been used to obtain an accurate arterial input function
providing MBF estimates in healthy and hypertrophic car-
diomyopathy subjects [23]. A potential limitation of this
method is the non-linear correlation between K1 and MBF
[17]; further investigation will be needed to evaluate the
quantitative accuracy in mice. In the present study, the
use of stress/rest ratio responses should help to minimize
the effects of any potential bias in the K1 index of MBF.
While the use of [11C]acetate for MBF quantification
has been validated at rest and during adenosine stress in
humans [17], it has not been separately validated in mice
or under catecholamine stress. In humans, exercise and
dobutamine stress have been used with [11C]acetate to
assess MBF and oxidative metabolism reserve through
stimulation of the sympathetic system and through ad-
renergic receptor activation [36,37]. In the present study,
we used the tracer uptake rate constant (K1) as an index
of MBF to assess the response to adrenergic stimulation
using NE and SB. Estimation of absolute MBF derived
from the [11C]acetate K1 values in mice would require
the use of a species-specific tracer extraction function,
which has not been published to our knowledge. An oxi-
dative stress response to catecholamines might affect the
tracer k2 values reflecting the rate of oxidative metabol-
ism and hence changes in the oxygen extraction fraction
(OEF) under NOS and α-adrenergic inhibition as indi-
cated in Table 3. Conversely, oxidative stress seems un-
likely to affect the initial tracer uptake rate (K1) which
reflects diffusion and transport across the capillary and
cell membranes [37].
Partial-volume and spillover effects in cardiac micro-
PET imaging have been a challenge in the past for tracer
kinetic modeling analysis. The present study included
validation of the image-derived input function (Figure 1)
and geometric spillover correction to obtain accuratequantitative data, similar to previous studies [38]. A 10-s
shift of the inferior VC blood curve was included to ac-
count for the venous to arterial transport delay, whereas
dispersion was not observed using the controlled slow-
bolus tracer injection. Similar MBFi values were obtained
using both the inferior VC and STD arterial sampled
blood input curves, confirming the accuracy of the image-
derived VC input curve [24].
Conclusions
Low-dose salbutamol β2-adrenergic receptor stimulation
induces coronary-specific and NO-mediated endothelium-
dependent vasodilatation. Salbutamol-stress [11C]acetate
micro-PET imaging of EFRNOM may be suitable for assess-
ment of coronary endothelial dysfunction in small animal
models of disease and evaluation of new therapies. The
EFRNOM response to low-dose SB-stress was exclusively
NO-mediated, and the method may be translated easily to
human studies.
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